John Allan, MD, Weill Cornell Medicine

Dr Allan on the Importance of BTK Inhibitors and BCL2 Inhibitors in CLL

December 1st 2023

John N. Allan, MD, discusses the importance of understanding fixed-duration treatment approaches with BTK inhibitors and BCL2 inhibitors in patients with chronic lymphocytic leukemia, highlighting data within this treatment armamentarium.

CLL: Final Thoughts

September 7th 2021

An expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.

Emerging Agents for R/R CLL

September 7th 2021

Experts discuss emerging agents for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

PI3K inhibitors for R/R CLL

August 31st 2021

An overview of data for PI3K inhibitors for in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

CLL: Venetoclax in the R/R Setting

August 31st 2021

Experts in chronic lymphocytic leukemia (CLL) discuss retreating patients with venetoclax.

High-Risk Patients With R/R CLL

August 24th 2021

A discussion about treatment for high-risk patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

CLL: BTK Inhibitors in the R/R Setting

August 24th 2021

Nicole Lamanna, MD, provides an overview of Bruton's tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL) in the relapsed/refractory (R/R) setting.

CLL: GLOW Trial Overview

August 17th 2021

Steven Coutre, MD, provides an overview of the phase 3 GLOW trial, as well as other novel and emerging combinations for the treatment of chronic lymphocytic leukemia (CLL).

CLL Therapies: Novel Combinations

August 17th 2021

John Allen, MD, provides an overview of data looking at emerging combinations as initial therapy for chronic lymphocytic leukemia (CLL).

BCL2 Inhibitors in Previously Untreated CLL

August 10th 2021

Experts discuss the optimal approach for choosing between a Bruton tyrosine kinase (BTK) inhibitor–based therapy vs a BCL2 inhibitor–based regimen for frontline chronic lymphocytic leukemia (CLL) therapy.

ALPINE Study: Zanubrutinib vs Ibrutinib in R/R CLL

August 10th 2021

An overview of the h ALPINE trial of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Mitigating Toxicities Associated With BTK Inhibitors

August 3rd 2021

A continuing discussion about the implications of toxicities with BTK inhibitors.

Safety and Efficacy of BTK Inhibitors in CLL

August 3rd 2021

A discussion about managing toxicities associated with Bruton tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL).

BTK Inhibitors as Frontline Treatment for CLL

July 27th 2021

Leukemia experts provide their personal experience using Bruton tyrosine kinase (BTK) inhibitors to treat patients with chronic lymphocytic leukemia (CLL) in the first-line setting.

Long-Term Experience With Ibrutinib in CLL

July 27th 2021

Jennifer Woyach, MD, discusses her experience using ibrutinib for chronic lymphocytic leukemia (CLL) in the first-line setting.

CLL: Prognostic Markers

July 20th 2021

An overview of prognostic models in chronic lymphocytic leukemia (CLL).

Prognostic Factors in Chronic Lymphocytic Leukemia

July 20th 2021

A discussion about prognostic factors in patients with newly diagnosed chronic lymphocytic leukemia (CLL).

Molecular Testing for Newly Diagnosed CLL

July 13th 2021

Ehab Attallah, MD, provides an overview of molecular testing for patients with newly diagnosed chronic lymphocytic leukemia (CLL).

CLL: Evolution of Treatment

July 13th 2021

William Wierda, MD, PhD, leads a panel of experts in a discussion pertaining to the treatment of chronic lymphocytic leukemia (CLL), beginning with the evolving treatment landscape.

Future Directions in CLL

July 30th 2020